Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ALKEM LABORATORIES vs PROCTER & GAMBLE HEALTH - Comparison Results

PROCTER & GAMBLE HEALTH 
   Change

Merck, the Indian arm of Merck KgaA (Germany), is a relatively smaller player among MNC pharma majors in the country. Merck has two business segments namely Pharmaceuticals and Chemicals. The pharmaceutical business, accounting for 68% of total sales... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ALKEM LABORATORIES PROCTER & GAMBLE HEALTH ALKEM LABORATORIES/
PROCTER & GAMBLE HEALTH
 
P/E (TTM) x 25.0 59.5 41.9% View Chart
P/BV x 6.0 7.3 82.1% View Chart
Dividend Yield % 0.8 6.5 12.5%  

Financials

 ALKEM LABORATORIES   PROCTER & GAMBLE HEALTH
EQUITY SHARE DATA
    ALKEM LABORATORIES
Mar-20
PROCTER & GAMBLE HEALTH
Dec-18
ALKEM LABORATORIES/
PROCTER & GAMBLE HEALTH
5-Yr Chart
Click to enlarge
High Rs2,7203,549 76.6%   
Low Rs1,6601,301 127.6%   
Sales per share (Unadj.) Rs697.9511.4 136.5%  
Earnings per share (Unadj.) Rs96.161.3 156.8%  
Cash flow per share (Unadj.) Rs117.374.0 158.4%  
Dividends per share (Unadj.) Rs25.00440.00 5.7%  
Dividend yield (eoy) %1.118.1 6.3%  
Book value per share (Unadj.) Rs515.2927.8 55.5%  
Shares outstanding (eoy) m119.5716.60 720.3%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.14.7 66.2%   
Avg P/E ratio x22.839.6 57.6%  
P/CF ratio (eoy) x18.732.8 57.0%  
Price / Book Value ratio x4.32.6 162.6%  
Dividend payout %26.0717.9 3.6%   
Avg Mkt Cap Rs m261,87940,257 650.5%   
No. of employees `00014.31.1 1,263.8%   
Total wages/salary Rs m15,0551,313 1,146.9%   
Avg. sales/employee Rs Th5,822.67,486.7 77.8%   
Avg. wages/employee Rs Th1,050.51,157.6 90.8%   
Avg. net profit/employee Rs Th802.0897.2 89.4%   
INCOME DATA
Net Sales Rs m83,4448,490 982.9%  
Other income Rs m1,042244 427.3%   
Total revenues Rs m84,4868,734 967.3%   
Gross profit Rs m14,7341,482 994.5%  
Depreciation Rs m2,528211 1,196.8%   
Interest Rs m6510-   
Profit before tax Rs m12,5981,514 831.9%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m066 0.0%   
Tax Rs m1,105563 196.4%   
Profit after tax Rs m11,4931,017 1,129.7%  
Gross profit margin %17.717.5 101.2%  
Effective tax rate %8.837.1 23.6%   
Net profit margin %13.812.0 114.9%  
BALANCE SHEET DATA
Current assets Rs m54,96015,343 358.2%   
Current liabilities Rs m32,4331,960 1,654.6%   
Net working cap to sales %27.0157.6 17.1%  
Current ratio x1.77.8 21.6%  
Inventory Days Days8049 163.3%  
Debtors Days Days7228 253.6%  
Net fixed assets Rs m32,7101,209 2,704.9%   
Share capital Rs m239166 144.0%   
"Free" reserves Rs m61,36815,235 402.8%   
Net worth Rs m61,60715,401 400.0%   
Long term debt Rs m1,5920-   
Total assets Rs m99,43317,595 565.1%  
Interest coverage x20.4NM-  
Debt to equity ratio x00-  
Sales to assets ratio x0.80.5 173.9%   
Return on assets %12.25.8 211.2%  
Return on equity %18.76.6 282.4%  
Return on capital %21.010.3 204.4%  
Exports to sales %19.10-   
Imports to sales %3.00-   
Exports (fob) Rs m15,917NA-   
Imports (cif) Rs m2,483NA-   
Fx inflow Rs m16,0611,636 981.6%   
Fx outflow Rs m2,4834,368 56.8%   
Net fx Rs m13,578-2,732 -497.0%   
CASH FLOW
From Operations Rs m5,851-1,304 -448.7%  
From Investments Rs m-7,41412,697 -58.4%  
From Financial Activity Rs m792-301 -263.4%  
Net Cashflow Rs m-73111,093 -6.6%  

Share Holding

Indian Promoters % 66.9 0.0 -  
Foreign collaborators % 0.0 51.8 -  
Indian inst/Mut Fund % 33.1 18.2 181.9%  
FIIs % 0.0 1.0 -  
ADR/GDR % 0.0 0.0 -  
Free float % 0.0 29.1 -  
Shareholders   68,381 28,591 239.2%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ALKEM LABORATORIES With:   CADILA HEALTHCARE  TTK HEALTHCARE  NEULAND LABS  BIOCON   J.B.CHEMICALS  

Compare ALKEM LABORATORIES With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Momentum Moves: The Week Gone By(Momentum Moves)

Nifty and Sensex ended the week gaining 0.60% and 0.52% respectively. Bulls started the week roaring but since Wednesday, the momentum seemed to be tiring.

Related Views on News

PROCTER & GAMBLE HEALTH Announces Quarterly Results (1QFY21); Net Profit Up 57.0% (Quarterly Result Update)

Aug 31, 2020 | Updated on Aug 31, 2020

For the quarter ended June 2020, PROCTER & GAMBLE HEALTH has posted a net profit of Rs 692 m (up 57.0% YoY). Sales on the other hand came in at Rs 6 bn (up 171.6% YoY). Read on for a complete analysis of PROCTER & GAMBLE HEALTH's quarterly results.

PROCTER & GAMBLE HEALTH Announces Quarterly Results (2QFY20); Net Profit Down 13.0% (Quarterly Result Update)

Nov 14, 2019 | Updated on Nov 14, 2019

For the quarter ended September 2019, PROCTER & GAMBLE HEALTH has posted a net profit of Rs 358 m (down 13.0% YoY). Sales on the other hand came in at Rs 2 bn (down 0.4% YoY). Read on for a complete analysis of PROCTER & GAMBLE HEALTH's quarterly results.

PROCTER & GAMBLE HEALTH Announces Quarterly Results (1QFY20); Net Profit Up 34.3% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, PROCTER & GAMBLE HEALTH has posted a net profit of Rs 441 m (up 34.3% YoY). Sales on the other hand came in at Rs 2 bn (up 6.1% YoY). Read on for a complete analysis of PROCTER & GAMBLE HEALTH's quarterly results.

PROCTER & GAMBLE HEALTH 2017-18 Annual Report Analysis (Annual Result Update)

Aug 8, 2019 | Updated on Aug 8, 2019

Here's an analysis of the annual report of PROCTER & GAMBLE HEALTH for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of PROCTER & GAMBLE HEALTH. Also includes updates on the valuation of PROCTER & GAMBLE HEALTH.

MERCK Announces Quarterly Results (4QFY19); Net Profit Up 79.2% (Quarterly Result Update)

May 13, 2019 | Updated on May 13, 2019

For the quarter ended March 2019, MERCK has posted a net profit of Rs 407 m (up 79.2% YoY). Sales on the other hand came in at Rs 2 bn (down 23.3% YoY). Read on for a complete analysis of MERCK's quarterly results.

More Views on News

Most Popular

My Top Stock Recommendation for 2021 and Beyond(Profit Hunter)

Jan 5, 2021

My new guide will show you the huge potential in future proof businesses.

'Essential' Smallcap Stock Recommendations(Profit Hunter)

Jan 8, 2021

The smallcap rally has enough steam left in it. If you haven't joined yet, it is still not too late.

Is Nifty Forming a Top(Fast Profits Daily)

Jan 8, 2021

The charts are telling the bulls to be cautious.

Why Gold Hit Lower Circuit(Fast Profits Daily)

Jan 11, 2021

Were you shocked that bullion prices hit lower circuits on Friday on the MCX? Find out why it happened...

Five Wishes and a Will(The Honest Truth)

Jan 4, 2021

Ajit Dayal on the investing strategy for 2021 and beyond.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

ALKEM LABORATORIES SHARE PRICE


Jan 15, 2021 (Close)

TRACK ALKEM LABORATORIES

  • Track your investment in ALKEM LABORATORIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ALKEM LABORATORIES

ALKEM LABORATORIES 5-YR ANALYSIS

COMPARE ALKEM LABORATORIES WITH

MARKET STATS